Cadent Therapeutics. (12/17/20). "Press Release: Cadent Therapeutics Enters Agreement to Be Acquired by Novartis". Cambridge, MA.

	Organisation	Cadent Therapeutics (US)
	Group	Novartis (Group)
	Organisation 2	Novartis AG (NYSE: NVS)
	Group	Novartis (Group)
	Product	negative allosteric modulator (NAM)
	Index term	Cadent Therapeutics–Novartis: investment, 202012– acquisition $210m upfront + $560m milestones ANNOUNCED
	Person	Morrison, Jodie (Cadent Therapeutics 202012 CEO formerly Tokai Pharmaceuticals 201503 CEO)

> Novartis gains full rights to Cadent’s NMDAr allosteric modulator program, including CAD-9303, a NMDAr-PAM, and MIJ-821, a NMDAr-NAM, which is currently being developed by Novartis under a 2015 license agreement.

> Additionally, Novartis gains Cadent’s pre-clinical programs and clinical stage movement disorder program.

> Cadent to receive $210 million upfront, with up to $560 million in milestones for a total of $770 million.

Cadent Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced today that it has reached a definitive agreement with Novartis, under which Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics. Upon the closing of the agreement, Cadent will receive a $210 million upfront payment and will be eligible for up to $560 million in milestone payments, for a total potential consideration of $770 million. Cadent Therapeutics launched in 2017 through the merger of Luc Therapeutics and Ataxion Therapeutics, with a focus on small molecules targeting neuronal ion channels.

The acquisition will give Novartis full rights to Cadent’s neuroscience portfolio, including its NMDAr program, which consists of two clinical programs: CAD-9303, a NMDAr positive allosteric modulator, and MIJ-821, a NMDAr negative allosteric modulator, which was licensed to Novartis in 2015. Additionally, Novartis will gain full rights to CAD-1883, a clinical stage SK channel positive allosteric modulator in development for movement disorders.

“Since the company’s launch, the Cadent team has been focused on building a portfolio of next-generation small molecule treatments for cognitive, mood, and movement disorders,” said Jodie Morrison, Chief Executive Officer of Cadent Therapeutics. “The expertise of Novartis in development of CNS therapeutics – something we have witnessed first-hand in our existing collaboration — provides an ideal foundation for continued advancement of the Cadent pipeline and will ensure the broad potential of these drugs is realized for patients.”

The transaction has been approved by the board of directors and stockholders of Cadent Therapeutics. Cadent and Novartis anticipate the transaction will close during the first quarter of 2021. Closing of the transaction is subject to customary closing conditions, including antitrust review pursuant to the Hart-Scott-Rodino premerger notification program.

ABOUT CADENT THERAPEUTICS

About Cadent Therapeutics

Cadent Therapeutics is creating therapies for the treatment of cognitive, mood, and movement disorders. The company combines target specificity, patient selection, drug design and optimization, and novel quantitative endpoints to create first-in-class molecules to treat cognitive and movement disorders. Cadent Therapeutics is rapidly advancing its pipeline of positive allosteric modulators within indications including schizophrenia and movement disorders. The company has an exclusive license and collaboration agreement with Novartis to develop a negative allosteric modulator, now in Phase 2 for the treatment of treatment resistant depression. Investors include Atlas Venture, Cowen Healthcare Investments, Qiming Venture Partners, Access Industries, Clal Biotechnology Industries, Novartis Corporate and Slater Technology Fund. For more information, please visit cadenttx.com.

– – – – – – – – – – – – – – – – –
Contacts
– – – – – – – – – – – – – – – – –

Investors:
Maeve Conneighton, maeve@argotpartners.com
212.600.1902

Media:
David Rosen, david.rosen@argotpartners.com
212.600.1902

Record changed: 2021-04-27